NASDAQ : LRMR
Larimar Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 247.39M |
| Enterprise Value | 96.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.88M |
| Shares Outstanding | 104.38M |
| Shares Change (YoY) | +40.23% |
| Shares Change (QoQ) | +15.65% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 49.13% |
| Float | 57.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 8.23 |
| PB Ratio | 2.02 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.70 |
| Quick Ratio | 4.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -139.63% |
| Return on Assets (ROA) | -70.96% |
| Return on Invested Capital (ROIC) | -87.12% |
| Return on Capital Employed (ROCE) | -136.49% |
| Weighted Average Cost of Capital (WACC) | 7.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.43M |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -39.07% |
| 50-Day Moving Average | 3.18 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 41.30 |
| Average Volume (20 Days) | 1,526,250 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.66M |
| Short Previous Month | 15.37M |
| Short % of Shares Out | 14.05% |
| Short % of Float | 25.33% |
| Short Ratio (days to cover) | 8.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -178.99M |
| Pretax Income | -172.61M |
| Net Income | -172.61M |
| EBITDA | -178.69M |
| EBIT | -178.99M |
| Earnings Per Share (EPS) | -$1.93 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 156.27M |
| Total Debt | 4.96M |
| Net Cash | 151.31M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 127.38M |
| Book Value Per Share | 1.22 |
| Working Capital | 126.51M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -155.92M |
| Capital Expenditures | -153,000 |
| Depreciation & Amortization | 301,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -156.08M |
| FCF Per Share | -$1.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -40.23% |
| Shareholder Yield | -40.23% |
| Earnings Yield | -81.26% |
| FCF Yield | -62.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.40 |
| Price Target Difference | 507.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |